Lorbrena

Chemical Namelorlatinib
Dosage FormTablet (oral; 25 mg, 100 mg)
Drug ClassKinase inhibitors
SystemRespiratory
CompanyPfizer Inc.
Approval Year2018

Indication

  • To treat anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other anaplastic lymphoma kinase inhibitor for metastatic disease.
  • To treat anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer whose disease has progressed on alactinib as the first anaplastic lymphoma kinase inhibitor therapy for metastatic disease.
  • To treat anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer whose disease has progressed on ceritinib as the first anaplastic lymphoma kinase inhibitor therapy for metastatic disease.
Last updated on 11/4/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Lorbrena (Lorlatinib) Prescribing Information 2018Pfizer Inc., New York, NY